Michael Martin
Gründer bei apelab SARL
Profil
Michael Martin is the founder of apelab SARL, which was founded in 2014, where he holds the title of Chief Technology Officer.
He currently holds the position of Vice President-Finance at CSA Group.
Mr. Martin received his undergraduate degree from the University of London and another undergraduate degree from University College London.
Aktive Positionen von Michael Martin
Unternehmen | Position | Beginn |
---|---|---|
CSA Group
CSA Group Miscellaneous Commercial ServicesCommercial Services CSA Group engages in the provision of testing and certification services. It offers standards development; training and education programs; and personnel certification services. The company was founded in 1919 and is headquartered in Toronto, Canada. | Finanzdirektor/CFO | - |
apelab SARL
apelab SARL Packaged SoftwareTechnology Services apelab SARL operates as a production studio that specializes in interactive storytelling for virtual reality and mobile devices. It focuses on creating accessible and engaging user experiences through compelling storyworlds and innovative gameplays. The company was founded by Emilie Joly, Maria Beltran Reyes, Sylvain Joly, and Michael Martin on March 10, 2014 and is headquartered in Les Acacias, Switzerland. | Gründer | 10.03.2014 |
Ehemalige bekannte Positionen von Michael Martin
Unternehmen | Position | Ende |
---|---|---|
AXION INTERNATIONAL HOLDINGS INC. | Direktor/Vorstandsmitglied | 26.05.2009 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Vertrieb & Marketing | 01.11.2006 |
Axton Manufacturing Ltd. | Finanzdirektor/CFO | 01.01.2003 |
Johnson Enterprises Ltd. | Finanzdirektor/CFO | 01.01.1991 |
Coopers & Lybrand International
Coopers & Lybrand International Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., Coopers & Lybrand International is a company based in Toronto, Canada. | Corporate Officer/Principal | 01.01.1989 |
Ausbildung von Michael Martin
University of London | Undergraduate Degree |
University College London | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 9 |
---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
Peat Marwick Mitchell & Co. | Commercial Services |
Coopers & Lybrand International
Coopers & Lybrand International Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., Coopers & Lybrand International is a company based in Toronto, Canada. | Commercial Services |
Axion International Holdings, Inc.
Axion International Holdings, Inc. Industrial SpecialtiesProcess Industries Axion International Holdings, Inc. manufactures markets and sells composite rail ties and structural building products. It delivers tested, proven and superior green solutions to plastics manufacturers and infrastructure needs around the globe through its business segments. The firm offers ECOTRAX rail products, such as main line, road crossing, tunnel-ties and tunnel-tie systems, pre-plated ties, and switch ties. The company was founded by James Joseph Kerstein in 1981 and is headquartered in Zanesville, OH. | Process Industries |
Galactic Resources Ltd. | Non-Energy Minerals |
Axton Manufacturing Ltd. | |
Johnson Enterprises Ltd. | |
CSA Group
CSA Group Miscellaneous Commercial ServicesCommercial Services CSA Group engages in the provision of testing and certification services. It offers standards development; training and education programs; and personnel certification services. The company was founded in 1919 and is headquartered in Toronto, Canada. | Commercial Services |
apelab SARL
apelab SARL Packaged SoftwareTechnology Services apelab SARL operates as a production studio that specializes in interactive storytelling for virtual reality and mobile devices. It focuses on creating accessible and engaging user experiences through compelling storyworlds and innovative gameplays. The company was founded by Emilie Joly, Maria Beltran Reyes, Sylvain Joly, and Michael Martin on March 10, 2014 and is headquartered in Les Acacias, Switzerland. | Technology Services |